Literature DB >> 29410939

Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI).

Søren D Østergaard1,2,3, Mark G A Opler1,2,3, Christoph U Correll1,2,3.   

Abstract

There is currently a "measurement gap" between research and clinical care in schizophrenia. The main reason behind this gap is that the most widely used rating scale in schizophrenia research, the 30-item Positive and Negative Syndrome Scale (PANSS), takes so long to administer that it is rarely used in clinical practice. This compromises the translation of research findings into clinical care and vice versa. The aim of this paper is to discuss how this measurement gap can be closed. Specifically, the main points of discussion are 1) the practical problems associated with using the full 30-item PANSS in clinical practice; 2) how the brief, six-item version of the Positive and Negative Syndrome Scale (PANSS-6) was derived empirically from the full 30-item PANSS and what the initial results obtained with PANSS-6 entail; and 3) how PANSS-6 ratings, guided by the newly developed, 15-25-minute, stand-alone Simplified Negative and Positive Symptoms Interview (SNAPSI), might help bridge the measurement gap between research and clinical care in schizophrenia. The full 30-item PANSS is often used in research studies, but is too time consuming to allow for routine clinical use. Recent studies suggest that the much briefer PANSS-6 is a psychometrically valid measure of core positive and negative symptoms of schizophrenia and that the scale is sensitive to symptom improvement following pharmacological treatment. SNAPSI is a brief interview that yields the information needed to rate PANSS-6 (and other brief rating scales). We believe that PANSS-6 ratings guided by SNAPSI will help bridge the measurement gap between research and clinical care in schizophrenia.

Entities:  

Keywords:  Schizophrenia; measurement-based care; psychometrics; rating scale

Year:  2017        PMID: 29410939      PMCID: PMC5788253     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  19 in total

1.  The brief negative symptom scale: psychometric properties.

Authors:  Brian Kirkpatrick; Gregory P Strauss; Linh Nguyen; Bernard A Fischer; David G Daniel; Angel Cienfuegos; Stephen R Marder
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

2.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.

Authors:  R L Spitzer; J B Williams; M Gibbon; M B First
Journal:  Arch Gen Psychiatry       Date:  1992-08

3.  Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.

Authors:  Myrto T Samara; Claudia Leucht; Mariska M Leeflang; Ion-George Anghelescu; Young-Chul Chung; Benedicto Crespo-Facorro; Helio Elkis; Kotaro Hatta; Ina Giegling; John M Kane; Monica Kayo; Martin Lambert; Ching-Hua Lin; Hans-Jürgen Möller; José María Pelayo-Terán; Michael Riedel; Dan Rujescu; Benno G Schimmelmann; Alessandro Serretti; Christoph U Correll; Stefan Leucht
Journal:  Am J Psychiatry       Date:  2015-06-05       Impact factor: 18.112

4.  The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.

Authors:  Søren D Østergaard; Leslie Foldager; Ole Mors; Per Bech; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

5.  Examination of the Positive and Negative Syndrome Scale factor structure and longitudinal relationships with functioning in early psychosis.

Authors:  Michael W Best; Michael Grossman; L Kola Oyewumi; Christopher R Bowie
Journal:  Early Interv Psychiatry       Date:  2014-10-02       Impact factor: 2.732

6.  The usefulness of rating scales in patients with schizophrenia.

Authors:  W Wolfgang Fleischhacker
Journal:  Acta Psychiatr Scand       Date:  2016-06       Impact factor: 6.392

7.  A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.

Authors:  M M Singh; S R Kay
Journal:  Psychopharmacologia       Date:  1975-08-21

8.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

Authors:  D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

Review 9.  Quantifying clinical relevance in the treatment of schizophrenia.

Authors:  Christoph U Correll; Taishiro Kishimoto; Jimmi Nielsen; John M Kane
Journal:  Clin Ther       Date:  2011-12       Impact factor: 3.393

10.  PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.

Authors:  S D Østergaard; O M Lemming; O Mors; C U Correll; P Bech
Journal:  Acta Psychiatr Scand       Date:  2015-11-12       Impact factor: 6.392

View more
  4 in total

Review 1.  Physical Activity, Positive and Negative Symptoms of Psychosis, and General Psychopathology among People with Psychotic Disorders: A Meta-Analysis.

Authors:  Ernest Swora; Monika Boberska; Ewa Kulis; Nina Knoll; Jan Keller; Aleksandra Luszczynska
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

2.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

3.  Using ecological momentary assessment for patients with psychosis posthospitalization: Opportunities for mobilizing measurement-based care.

Authors:  Ethan Moitra; Hyun Seon Park; Dror Ben-Zeev; Brandon A Gaudiano
Journal:  Psychiatr Rehabil J       Date:  2020-04-16

4.  Effects of Transcranial Direct Current Stimulation (tDCS) and Approach Bias Modification (ABM) training on food cravings in people taking antipsychotic medication.

Authors:  Luiza Grycuk; Gemma Gordon; Fiona Gaughran; Iain C Campbell; Ulrike Schmidt
Journal:  Trials       Date:  2020-03-06       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.